Circadian Rhythm Amplification to Restore Network Oscillation Synchronization

Circadian Rhythm Amplification connectomics market 36% proposed
Composite
35%
Novelty
65%
Feasibility
20%
Impact
35%
Mechanistic
45%
Druggability
25%
Safety
45%
Confidence
35%

Mechanistic description

Circadian Rhythm Amplification to Restore Network Oscillation Synchronization

Evidence for (5)

  • Circadian dysfunction is bidirectional with AD - disruption increases risk, pathology disrupts rhythms

    PMID:28934252

  • Glymphatic Aβ clearance occurs primarily during sleep and is activity-dependent

    PMID:24317693

  • Hub regions show high metabolic activity and are preferentially affected by circadian disruption

    PMID:20644199

  • RORα agonists activate circadian target genes and show neuroprotective effects

    PMID:23954313

  • Suvorexant (orexin antagonist) showed modest amyloid biomarker improvement in Phase 2

    PMID:NCT02727959

Evidence against (5)

  • RORα agonist SR1078 developed for cancer - no brain penetration data, no AD validation

    PMID:23954313

  • BMAL1 is not druggable - transcription factor without ligand-binding pocket

    PMID:23954313

  • Melatonin and sleep hygiene interventions failed to demonstrate disease-modifying effects

    PMID:28934252

  • Glymphatic relevance in humans - and in AD - remains controversial

    PMID:31501667

  • Circadian disruption may be biomarker, not cause - downstream of AD pathology